Moderna, Inc. (MRNA) Options Risk Score
Real-time risk analysis for MRNA options traders — updated every 30 minutes.
Data last updated: 2026-07-23
Run a full MRNA options risk analysis
See the complete risk breakdown — news catalysts, SEC filings, legal proceedings, earnings overlap, IV vs HV, options flow and Expected Move — all in one scan.
Scan MRNA Now — Free →
Is it risky to sell options on Moderna, Inc. (MRNA) right now?
For a 4-week expiry, Moderna, Inc. (MRNA) carries an options catalyst-risk score of 100 out of 100 (HIGH). That score is driven by an upcoming earnings report, 5 recent news items, 7 active legal filings and 47 clinical-trial catalysts falling inside the 4-week window. On TickerRisk's scale 70 and above is HIGH, so a known event is scheduled inside this window — selling premium on MRNA here is a bet on that event rather than on time decay. The score measures scheduled event exposure, not which way the stock will move.
MRNA shows an IV Rank of 83 — implied volatility is near the top of its own one-year range, so MRNA options are historically expensive, which favours premium-selling strategies, with a current implied volatility of about 92%. Read IV Rank alongside the catalyst score: it says how expensive MRNA options are, while the score says whether that price is justified by a scheduled event.
The 2026-07-31 earnings report sits inside a standard monthly expiry for MRNA, so implied volatility should stay bid into the date and drop sharply once it passes.
TickerRisk provides risk scoring for informational purposes only. This is not financial advice. Options trading involves substantial risk of loss. Full disclaimer